Abbott Laboratories’ (ABT) “Overweight” Rating Reiterated at Piper Sandler

Piper Sandler reissued their overweight rating on shares of Abbott Laboratories (NYSE:ABT) in a research report sent to investors on Friday,Benzinga reports. They currently have a $118.00 price objective on the healthcare product maker’s stock, up from their prior price objective of $115.00.

A number of other research analysts also recently commented on ABT. Leerink Partners cut their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Evercore lowered their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Barclays cut their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Citigroup reduced their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Sanford C. Bernstein lowered their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Price Performance

ABT opened at $100.71 on Friday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The business’s fifty day simple moving average is $89.89 and its 200-day simple moving average is $102.01. The company has a market capitalization of $175.41 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the firm posted $1.26 earnings per share. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Insider Buying and Selling

In other news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Institutional Trading of Abbott Laboratories

A number of institutional investors have recently made changes to their positions in the business. 4WEALTH Advisors Inc. grew its stake in Abbott Laboratories by 25.3% during the 2nd quarter. 4WEALTH Advisors Inc. now owns 9,520 shares of the healthcare product maker’s stock worth $883,000 after buying an additional 1,923 shares during the last quarter. Liberty Capital Management Inc. acquired a new position in Abbott Laboratories during the 2nd quarter valued at about $3,140,000. Merit Financial Group LLC raised its stake in Abbott Laboratories by 22.0% in the second quarter. Merit Financial Group LLC now owns 77,835 shares of the healthcare product maker’s stock valued at $7,063,000 after buying an additional 14,030 shares during the last quarter. Vaquero Private Wealth Ltd. acquired a new stake in Abbott Laboratories in the second quarter worth about $180,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Abbott Laboratories by 1.5% during the second quarter. Farther Finance Advisors LLC now owns 73,946 shares of the healthcare product maker’s stock worth $6,714,000 after acquiring an additional 1,128 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.